Bellevue Asset Management (Switzerland)’s PTC Therapeutics PTCT Stock Holding History

Bellevue Asset Management (Switzerland)’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	$1.78M	Buy	+55,000	New	+$1.62M	0.27%	89

Other funds holding PTCT

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Bellevue Asset Management (Switzerland)'s PTCT Position: Q4 2015 in Review

Bellevue Asset Management (Switzerland) opened a new position in PTC Therapeutics (PTCT) in Q4 2015: 55,000 shares worth $1.78M. The stake represents 0.27% of the portfolio and ranks #89 among its holdings.

141 funds tracked by Wall St. Rank hold PTCT as of Q4 2015.

Bellevue Asset Management (Switzerland) held 55,000 shares of PTC Therapeutics worth $1.78M as of Q4 2015.
PTC Therapeutics was a new Bellevue Asset Management (Switzerland) position in Q4 2015.
PTC Therapeutics made up 0.27% of Bellevue Asset Management (Switzerland)'s portfolio in Q4 2015, its #89 holding.
141 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2015.

Based on Bellevue Asset Management (Switzerland)'s 13F filing for Q4 2015, filed 12 Feb 2016.